Businessweek

sorders. Stromedix, Inc.’s primary candidate, STX-100, is in a Phase 2 study for idiopathic pulmonary fibrosis, a disease in which lung tissue becomes scarred over time. Strategy The company’s research and development strategy is to discover and develop first-in-class molecules or best-in-class molecules that improve safety or efficacy for unmet medical needs. Patents and Other Proprietary Rights The company’s trademarks include RITUXAN and AVONEX and are covered by trademark applications or registrations in the U.S. Patent and Trademark Office (USPTO) and the patent or trademark offices of other countries. It also uses trademarks licensed from third parties, such as the mark TYSABRI, which the company licenses from Elan. AVONEX and Pegylated Beta Interferon: The company has non-exclusive rights under certain third-party patents and patent applications to manufacture, use, and sell AVONEX, including a patent owned by the Japanese Foundation for Cancer Research, which expires in 2013 in the U.S. Additionally, the company and third parties own pending U.S. patent applications related to recombinant interferon-beta protein and nucleic acid. Additional protection for its pegylated beta interferon is provided by patents and patent applications with expiration dates in 2021 in the U.S. and 2019 in the E.U., with the potential for patent term extension. TYSABRI: The company and its collaborator, Elan, have patents and patent applications covering TYSABRI in the U.S. and other countries. These patents and patent applications cover TYSABRI and related manufacturing methods, as well as various methods of treatment using the product. In the U.S., the principal patents covering the product and use of the product to treat MS generally expire between 2015 and 2020. Additional U.S. patents and applications covering other indications, including treatment of inflammatory bowel disease, and methods of manufacturing, generally expire between 2012 and 2020. In the rest of world, patents on the product and methods of manufacturing the product generally expire between 2015 and 2020, subject to any supplemental protection (patent term extension) certificates that might be obtained. In the rest of world, patents and patent applications covering methods of treatment using TYSABRI generally expire between 2012 and 2020. RITUXAN and Anti-CD20 Antibodies: The company has various U.S. patents and patent applications, and various corresponding foreign counterparts, directed to anti-CD20 antibody technology, including RITUXAN. The principal patents with claims to RITUXAN or its uses expire in the U.S. between 2015 and 2018 and in the rest of the world in 2013, subject to any available patent term extensions. In addition, the company and its collaborator, Genentech, have filed various patent applications directed to anti-CD20 antibodies and their uses to treat various diseases. Genentech, its collaborator on RITUXAN, has secured a license to five U.S. patents and counterpart U.S. and foreign patent applications assigned to Xoma Corporation that relate to chimeric antibodies against the CD20 antigen. These patents expire between 2007 and 2014. FAMPYRA: The company has a license under two European granted patents, various pending European patent applications, and various corresponding non-U.S. counterpart applications related to FAMPYRA. TECFIDERA: The company has various U.S. patents and patent applications, and various corresponding foreign counterparts, related to TECFIDERA. It also owns a patent application, recently determined to be allowable by the USPTO, which covers the dosing regimen (240 mg of dimethyl fumarate administered twice a day) stated on its label under current review at the FDA. Long-Lasting Recombinant Factors VIII and IX: The company has various U.S. patents and patent applications, and various corresponding foreign counterparts, related to its long-lasting recombinant Factor VIII and Factor IX product candidates and their use. These patents would expire in 2024 – 2025. Regulation The company is subject to various federal and foreign laws that govern its international business practices with respec